Canada - English - Health Canada

merz pharmaceuticals gmbh - incobotulinumtoxina - powder for solution - 100unit - incobotulinumtoxina 100unit - other miscellaneous therapeutic agents

Canada - English - Health Canada

merz pharmaceuticals gmbh - incobotulinumtoxina - powder for solution - 50unit - incobotulinumtoxina 50unit - other miscellaneous therapeutic agents

Canada - English - Health Canada

merz pharmaceuticals gmbh - incobotulinumtoxina - powder for solution - 100unit - incobotulinumtoxina 100unit - other miscellaneous therapeutic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinine bisulfate heptahydrate, quantity: 300 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate; carnauba wax; magnesium stearate; lactose monohydrate; colloidal anhydrous silica; purified talc; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; macrogol 4000 - treatment of malaria due to strains of p. falciparum resistant to chloroquine and the related 4-aminoquinolines.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - mefloquine hydrochloride, quantity: 274.09 mg (equivalent: mefloquine, qty 250 mg) - tablet, uncoated - excipient ingredients: ammonium alginate; crospovidone; lactose monohydrate; magnesium stearate; microcrystalline cellulose; purified talc; maize starch; poloxamer - malaria treatment: lariam is indicated for the treatment of acute attacks of malaria due to p.falciparum infection resistant to conventional antimalarial drugs. following therapy of mixed p.falciparum/p.vivax malaria with lariam relapse prophylaxis with an 8-aminoquinoline derivative (e.g. primaquine) should be considered in order to eliminate liver forms of p.vivax. malaria prophylaxis: for travellers to countries with documented chloroquine and antifolate combination ( [sulfadoxine/pyrimethamine] / [dapsone/pyrimethamine] ) resistant p.falciparum malaria, who are considered to be at high risk for malaria in view of their residence or travel (of up to 3 months duration) through rural areas (between the dusk to dawn period). for travellers hypersensitive to sulphonamides and sulphones, who are considered to be at high risk for malaria in view of their residence or travel (of up to 3 months duration) through rural areas, (between the dusk to dawn period) in countries with high level chloroquine-resistant p.fal

Ireland - English - HPRA (Health Products Regulatory Authority)

clear pharmacy - hydroxychloroquine sulphate - film coated tablet - 200 milligram - aminoquinolines

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - hydroxychloroquine sulfate - film-coated tablet - 200 milligram(s) - aminoquinolines; hydroxychloroquine

Israel - English - Ministry of Health

sanofi israel ltd - hydroxychloroquine sulfate - film coated tablets - hydroxychloroquine sulfate 200 mg - hydroxychloroquine - hydroxychloroquine - plaquenil is indicated for the suppressive treatment and treatment of acute attacks of malaria due to plasmodium vivax, p. malaria. p. ovale and susceptible strains of p. falciparum it is also indicated for the treatment of discoid and sustemic lupus erythematosus and rheumatoid arthritis.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - malaria hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p. falclparum, p. malariae, p. ovale, and p. vlvax. hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the centers for disease control and prevention (cdc) malaria website (http://www.cdc.gov/malaria). lupus erythematosus hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. rheumatoid arthritis hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. use of hydroxychloroquine sulfate tablets is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p. falciparum, p. malariae, p. ovale, and p. vivax. hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria: prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the centers for disease control and prevention (cdc) malaria website (http://www.cdc.gov/malaria). hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. use of hydroxychloroquine sulfate tablets are contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.